CAROLINA CVOT Neutral; No Impact to OAD Market
BI/Lilly announced that the CAROLINA CVOT met the primary endpoint of non-inferiority on 3P-MACE vs. glimepiride. Full results from the study are scheduled to be presented on June 10 at the ADA conference. Below, FENIX provides thoughts on CAROLINA and how OAD market dynamics are unlikely to be affected, continuing the slow decline of SU volume share.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.